{"id":"phase-1-risperidone","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Weight gain"},{"rate":"20-30","effect":"Sedation"},{"rate":"40-50","effect":"Prolactin elevation"},{"rate":"10-20","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Orthostatic hypotension"},{"rate":"10-15","effect":"Akathisia"}]},"_chembl":{"chemblId":"CHEMBL85","moleculeType":"Small molecule","molecularWeight":"410.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Risperidone antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis, while also blocking serotonin 5-HT2A receptors which may enhance antipsychotic efficacy and reduce extrapyramidal side effects. This dual mechanism makes it an atypical antipsychotic with a favorable side effect profile compared to first-generation agents.","oneSentence":"Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:38.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar disorder (acute mania)"},{"name":"Irritability associated with autism spectrum disorder"}]},"trialDetails":[{"nctId":"NCT04624243","phase":"PHASE2","title":"Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-15","conditions":"Schizophrenia","enrollment":499},{"nctId":"NCT01625897","phase":"PHASE2, PHASE3","title":"A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2012-05","conditions":"Schizophrenia","enrollment":125},{"nctId":"NCT06276361","phase":"PHASE1","title":"Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2023-09-26","conditions":"Schizophrenia","enrollment":58},{"nctId":"NCT07116850","phase":"NA","title":"Adjunctive iTBS for First-Episode Schizophrenia","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2024-01-01","conditions":"Schizophrenia Disorder","enrollment":100},{"nctId":"NCT04940039","phase":"PHASE4","title":"A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings","status":"COMPLETED","sponsor":"Janssen-Cilag International NV","startDate":"2021-07-22","conditions":"Schizophrenia","enrollment":93},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT04201834","phase":"PHASE2","title":"Risperidone for the Treatment of Huntington's Disease Involuntary Movements","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2020-08-13","conditions":"Huntington Disease, Chorea","enrollment":6},{"nctId":"NCT04418466","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant","status":"COMPLETED","sponsor":"Delpor, Inc.","startDate":"2021-04-01","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT06218979","phase":"PHASE1","title":"KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2023-12-08","conditions":"Psychosis, Food-drug Interaction","enrollment":12},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT03055338","phase":"PHASE2","title":"An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-08","conditions":"Schizophrenia, Acute Episode","enrollment":224},{"nctId":"NCT03522168","phase":"","title":"Long-term Antipsychotic Pediatric Safety Trial","status":"COMPLETED","sponsor":"Duke University","startDate":"2019-01-10","conditions":"Weight, Body","enrollment":509},{"nctId":"NCT02366897","phase":"NA","title":"Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2017-02-21","conditions":"Drug-induced Extrapyramidal Side Effects","enrollment":21},{"nctId":"NCT03323437","phase":"PHASE4","title":"Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2017-09-15","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":26},{"nctId":"NCT01788774","phase":"PHASE1","title":"Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths","status":"COMPLETED","sponsor":"Rovi Pharmaceuticals Laboratories","startDate":"2013-04","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":36},{"nctId":"NCT04512066","phase":"PHASE2","title":"A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-09-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":287},{"nctId":"NCT03503318","phase":"PHASE3","title":"Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2018-04-27","conditions":"Schizophrenia","enrollment":544},{"nctId":"NCT00845026","phase":"PHASE2","title":"A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2009-03","conditions":"Schizophrenia","enrollment":261},{"nctId":"NCT01052103","phase":"PHASE2","title":"A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms","status":"COMPLETED","sponsor":"Denovo Biopharma LLC","startDate":"2010-01","conditions":"Schizophrenia","enrollment":167},{"nctId":"NCT00711269","phase":"PHASE3","title":"Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2008-06-27","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT03955549","phase":"PHASE3","title":"Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial","status":"COMPLETED","sponsor":"Agiad Psychiatry Hospital","startDate":"2019-05-01","conditions":"Schizophrenia Spectrum and Other Psychotic Disorders","enrollment":99},{"nctId":"NCT03887754","phase":"PHASE2","title":"Therapeutic Issues for Autism","status":"COMPLETED","sponsor":"Minia University","startDate":"2016-01","conditions":"Autism Spectrum Disorder","enrollment":80},{"nctId":"NCT02109562","phase":"PHASE3","title":"Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":354},{"nctId":"NCT01677377","phase":"PHASE2","title":"Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02875340","phase":"PHASE2","title":"A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"ValiSeek Limited","startDate":"2016-10","conditions":"Carcinoma, Non-Small-Cell Lung, Adenocarcinoma","enrollment":8},{"nctId":"NCT01175135","phase":"PHASE2","title":"An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-10","conditions":"Schizophrenia","enrollment":259},{"nctId":"NCT00272597","phase":"PHASE4","title":"Risperidone LA Heathcare Resource Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2005-09","conditions":"Psychosis, Schizophrenia","enrollment":30},{"nctId":"NCT00000317","phase":"PHASE2","title":"Early Phase II Trials for Cocaine Medication Development - 1","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"1996-08","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":31},{"nctId":"NCT02462473","phase":"PHASE2","title":"A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-05","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":9},{"nctId":"NCT02019329","phase":"PHASE1","title":"A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Schizophrenia","enrollment":32},{"nctId":"NCT02768649","phase":"PHASE1","title":"Single Ascending Dose Study of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2011-04","conditions":"Schizophrenia","enrollment":45},{"nctId":"NCT02765555","phase":"PHASE1","title":"First in Man Study of Safety, Tolerability and PK Profile of RBP-7000","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2010-03","conditions":"Schizophrenia","enrollment":12},{"nctId":"NCT00140426","phase":"PHASE4","title":"A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2004-08","conditions":"Anorexia Nervosa","enrollment":41},{"nctId":"NCT00641745","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":629},{"nctId":"NCT01234454","phase":"NA","title":"Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2002-01","conditions":"Schizophrenia","enrollment":34},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT01450514","phase":"PHASE2","title":"POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia","status":"COMPLETED","sponsor":"PharmaNeuroBoost N.V.","startDate":"2012-03","conditions":"Chronic Schizophrenia, Schizoaffective Disorder","enrollment":7},{"nctId":"NCT01774435","phase":"PHASE1","title":"Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant","status":"COMPLETED","sponsor":"Endo Pharmaceuticals","startDate":"2012-10","conditions":"Schizophrenia","enrollment":35},{"nctId":"NCT01363349","phase":"PHASE2, PHASE3","title":"Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia","status":"TERMINATED","sponsor":"BioLineRx, Ltd.","startDate":"2011-05","conditions":"Schizophrenia, Cognitive Effect on Schizophrenic Patients","enrollment":269},{"nctId":"NCT02040883","phase":"PHASE4","title":"Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","startDate":"2014-02","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT00508157","phase":"PHASE4","title":"A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2007-11","conditions":"Metabolic Syndrome, Schizophrenia","enrollment":125},{"nctId":"NCT01086748","phase":"PHASE2","title":"A Study in Schizophrenia Patients","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-03","conditions":"Schizophrenia","enrollment":880},{"nctId":"NCT00794625","phase":"PHASE4","title":"Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)","status":"UNKNOWN","sponsor":"Joseph Blader","startDate":"2008-11","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":270},{"nctId":"NCT00573716","phase":"","title":"Comparison of Bone Mineral Density Changes During Tx With Risperidone or Aripiprazole in Adolescents","status":"COMPLETED","sponsor":"Creighton University","startDate":"2006-10","conditions":"Psychiatry","enrollment":60},{"nctId":"NCT00791232","phase":"PHASE1","title":"A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2003-03","conditions":"Schizophrenia","enrollment":113},{"nctId":"NCT01259973","phase":"PHASE1","title":"Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers","status":"UNKNOWN","sponsor":"Hospital Clinic of Barcelona","startDate":"2011-02","conditions":"Pharmacogenetics, Healthy","enrollment":24},{"nctId":"NCT00253149","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"","conditions":"Bipolar Disorders, Manic Disorder","enrollment":158},{"nctId":"NCT00250367","phase":"PHASE3","title":"A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"1997-10","conditions":"Bipolar Disorder, Manic Disorder","enrollment":151},{"nctId":"NCT00921804","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, and Tolerability of AZD8529 in Adult Schizophrenia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Schizophrenia","enrollment":296},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00352339","phase":"PHASE4","title":"The New Strategy for Pharmacological Treatment in People With Schizophrenia","status":"UNKNOWN","sponsor":"Inje University","startDate":"2006-08","conditions":"Schizophrenia","enrollment":90},{"nctId":"NCT00528359","phase":"","title":"β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2005-10","conditions":"Schizophrenia","enrollment":36},{"nctId":"NCT00626613","phase":"PHASE4","title":"The Relationship Between Risperdal Treatment and Quality of Life in Patients With Alzheimer's Disease and Behavioural and Psychological Symptoms of Dementia (BPSD)","status":"UNKNOWN","sponsor":"Jinan Mental Hospital","startDate":"","conditions":"Dementia, Alzheimer's Disease","enrollment":""},{"nctId":"NCT00004393","phase":"PHASE2","title":"Phase II Double Blind Placebo Controlled Trial of Risperidone in Tourette Syndrome","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1997-07","conditions":"Tourette Syndrome","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 1: Risperidone","genericName":"Phase 1: Risperidone","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Risperidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Schizophrenia, Bipolar disorder (acute mania), Irritability associated with autism spectrum disorder.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}